Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFα receptors

Annals of the Rheumatic Diseases

Volumn 60, Issue 2, 2001, Pages 133-139

  Berg, L ^a   Lampa, J ^a   Rogberg, S ^a   Van Vollenhoven, R ^a   Klareskog, L ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; COLLAGEN TYPE 2; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOST RESISTANCE; HUMAN; IMMUNITY; IMMUNOREACTIVITY; IMMUNOSTIMULATION; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, VIRAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CASE-CONTROL STUDIES; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035136526     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.60.2.133     Document Type: Article

References (40)

1. Inhibitors of tumor necrosis factor for rheumatoid arthritis
2. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
3. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis
4. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis
5. What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?
6. Interferon-γ production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1*0401 and HLA-DQ8
7. Down-regulation of the T cell receptor CD3ζ chain in rheumatoid arthritis (RA) and its influence on T cell responsiveness
8. Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis
9. Altered lymphocyte reactivity in rheumatoid arthritis
10. Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis
11. Depressed T-cell reactivity to recall antigens in rheumatoid arthritis
12. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis
13. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis
14. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis
15. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
16. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
17. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials
18. Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary culture
19. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
20. Long-term safety and efficacy of combination therapy with methotrexate (MTX) and etanercept (Enbrel®)
21. Altered T lymphocyte signaling in rheumatoid arthritis
22. Role of tumor necrosis factor-alpha in the regulation of activated synovial T cell growth: Down-regulation of synovial T cells in rheumatoid arthritis patients
23. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling
24. Prostaglandin E2 inhibits human T-cell proliferation after crosslinking of the CD3-Ti complex by directly affecting T cells at an early step of the activation process
25. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity
26. Increased expression of CD11b (Mo1) on peripheral blood monocytes of patients with rheumatoid arthritis
27. Phenotypic analysis of peripheral blood monocytes isolated from patients with rheumatoid arthritis
28. Monocyte activation in rheumatoid arthritis (RA): Increased integrin, Fc gamma and complement receptor expression and the effect of glucocorticoids
29. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis
30. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis
31. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: Potential implications for treatment
32. Survival, prognosis, and causes of death in rheumatoid arthritis
33. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study
34. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate
35. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
36. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus
37. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: Relevance to genetic predisposition to systemic lupus erythematosus
38. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
39. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
40. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group